Pharmacy Times
JULY 29, 2022
The immune responses to the Omicron variant waned substantially with neutralizing antibody levels decreasing 2.4- to 5.3-fold by 3 months after the booster dose.
Pharmaceutical Technology
JULY 29, 2022
Pfizer has reported a 53% operational growth in revenues to $27.7bn in the second quarter (Q2) of 2022 compared to $18.9bn in the same quarter last year. The rise in revenues was chiefly driven by robust contributions from Covid-19 therapies Paxlovid and Comirnaty. On an operational basis, the revenues rose by $128m or 1%, excluding Paxlovid and Comirnaty’s contributions.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
JULY 29, 2022
A majority of long-term care patients who received a fourth vaccination against COVID-19 were found to have increased protection against the omicron variant.
Pharmaceutical Technology
JULY 29, 2022
The Food and Drug Administration (FDA) has acc epted to review ImmunityBio’s Biologics License Application (BLA) for N-803 to treat Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) carcinoma in situ (CIS) patients with or without Ta or T1 disease. A decision from the regulatory agency on approval for the treatment is anticipated on 23 May next year.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharmacy Times
JULY 29, 2022
The pandemic saw reductions in the supply of methadone but no disruption to the supply of more easily accessible buprenorphine, though disparities in supply were observed across states.
Pharmaceutical Technology
JULY 29, 2022
The rate at which children are being identified with autism spectrum disorder (ASD) has tripled in the past two decades. While the prevalence was 1 in 150 children in 2000, it reached the rate of 1 in 44 in 2018, in the US, according to the Centers for Disease Control and Prevention. Some people with ASD can experience acute agitation and crisis behaviours.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharmaceutical Technology
JULY 29, 2022
Schizophrenia Awareness Day, marked on 25 July, is a national observance that aims to raise awareness about this mental illness. Schizophrenia is a chronic brain disorder that affects a person’s ability to function, such as thinking and feeling. According to GlobalData’s Epidemiology and Market Size database, epidemiologists estimate there are more than 21 million prevalent cases within the tracked 16 countries.
Pharmacy Times
JULY 29, 2022
The findings of the phase 1b/2 CHRYSALIS-2 cohort will be presented at the International Association for the Study of Lung Cancer 2022 World Conference on Lung Cancer.
Pharmaceutical Technology
JULY 29, 2022
Last week, CAMP4 Therapeutics announced the close of a $100 million Series B round , which will be used to advance their regulatory RNA (regRNA)-focused programs. Their use of regRNA technology provides a unique approach to treating rare conditions like urea cycle disorders. CAMP4’s CSO David Bumcrot PhD tells Pharmaceutical Technology that the company plans to see clinical trials go forward for their urea cycle disorder programs late next year.
Pharmacy Times
JULY 29, 2022
People who are afraid of shots or feel lightheaded and dizzy while near vaccine injection sites are less likely to get vaccinated against COVID-19.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
European Pharmaceutical Review
JULY 29, 2022
Researchers have constructed biohybrid microrobots, by equipping Escherichia coli bacteria with artificial components, that could one day offer a highly targeted and effective cancer treatment option. The team of scientists from the Physical Intelligence Department at the Max Planck Institute for Intelligent Systems combined robotics with E. coli bacteria to construct their innovative drug delivery system.
Pharmacy Times
JULY 29, 2022
Government’s database include health care professionals in many categories, including pharmacists.
European Pharmaceutical Review
JULY 29, 2022
Both the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) have endorsed a statement calling for international collaboration on integrating real-world evidence (RWE) into regulatory decision-making. The statement, published by the International Coalition of Medicines Regulatory Authorities (ICMRA), describes how collaboration between regulators and researchers that formed a critical aspect of the world’s COVID-19 response could be leveraged to enhance medicines regulatio
Pharmacy Times
JULY 29, 2022
Pharmacists highlight patient hesitations surrounding vaccinations and offer a multitude of approaches for alleviating these concerns.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmaceutical Commerce
JULY 29, 2022
OptimizeRx’s Steve Silvestro on how the healthcare sector is performing when it comes to patient care, and how the use of technology can positively impact that process.
pharmaphorum
JULY 29, 2022
Oliver Stohlmann’s Corporate Survival Hacks series draws on his experiences of working in local, regional, and global life science communications to offer some little tips for enjoying a big business career. This post recommends setting aside regular time for reflection to critically think through major opportunities, projects and issues in order to make well-considered, high-quality decisions.
Pharmacy Times
JULY 29, 2022
Evolutionary vaccine technologies driven by the COVID-19 pandemic are explored in a discussion led by Dr Cohen.
pharmaphorum
JULY 29, 2022
Patients with end-stage renal disease (ESRD) who are on dialysis often need to be treated with anticoagulants to prevent blood clots, but as a result, can experience bleeding side effects. Now, Ionis and Bayer think they have a new drug that could sidestep that risk. In a phase 2b RE-THINC trial, their experimental antisense-based Factor XI inhibitor fesomersen was able to achieve a “substantial and statistically significant” reduction in levels of the clotting factor, indicating it
Pharmacy Times
JULY 29, 2022
Fondaparinux sodium (Arixtra) is indicated for prophylaxis of deep vein thrombosis (DVT) in patients undergoing hip fracture surgery (including extended prophylaxis), hip replacement surgery, knee replacement surgery, or abdominal surgery.
Pharmaceutical Technology
JULY 29, 2022
As the full consequences of the COVID-19 virus started to emerge, and many industries found themselves having to either suspend operations or move to remote working, the biopharma sector found itself on the front line facing unprecedented challenges. The need for the sector to rapidly research, develop and test new vaccines had always been of critical importance, but in the context of a global pandemic and national lockdowns, it became even more so, with each part of the supply chain required to
Pharmacy Times
JULY 29, 2022
There is nothing that hurts us more when a pharmacist stands up and is not passionate about the job that we do and the care that we provide.
PharmExec
JULY 29, 2022
The use of biometric data and novel digital biomarkers in the administration of CAT-T therapy can both improve the safety profile and reduce patient burden of cancer treatment. Jaydev Thakkar, Chief Operating Officer at Biofourmis, will share how this data paired with clinical-grade algorithms can predict the onset of adverse events to allow for proactive intervention and improved patient outcomes.
Pharmacy Times
JULY 29, 2022
This month, we spoke with Tiago Reis Marques, MD, PhD, CEO of Pasithea Therapeutics, about ketamine and the future of the opioid epidemic.
Compounding Pharmacy of America
JULY 29, 2022
Palliative care is not a treatment to reduce or eliminate the condition or disease. It is a pain management process for those living with a serious, oftentimes life threatening illness. Through palliative care, patients and their families can focus on a comfortable quality of life. Discussing palliative care does not always mean a lack of […].
Pharmacy Times
JULY 29, 2022
Study shows that adult survivors of cancer had a 42% greater risk of CVD than people who did not have the disease.
The Honest Apothecary
JULY 29, 2022
I have noticed a tendency in some otherwise great healthcare leaders throughout my career to fall short of the influence they might have had by failing to, as I see it, balance passion and patience. Too much of one, or too little of the other, makes a lopsided leader whose impact can suddenly derail. Allow me to elaborate on this a bit, and try to offer some advice from my own experience.
pharmaphorum
JULY 29, 2022
AstraZeneca chief executive Pascal Soriot said this morning that strong revenue increases in 2022 – fuelled by its COVID-19 antibody Evusheld and oncology drugs – have allowed the company to boost its investment in R&D. The drugmaker reported (PDF) revenues up a third to $10.8 billion in the second quarter, allowing it to raise its sales forecast for the full year to growth of at least 20%, against earlier estimates in the high teens.
Pharmaceutical Technology
JULY 29, 2022
Pfizer (New York, New York) and Moderna’s (Cambridge, Massachusetts) Omicron-specific Covid-19 vaccines are in late-stage development, have demonstrated good efficacy against the variant and will likely be available to the public later this year to provide an additional booster and increase demand for injectable manufacturing. Despite the advanced stage of Covid-19 vaccination programmes in richer countries, which would suggest an approaching drop-off in contract manufacturing demand, there is s
PharmExec
JULY 29, 2022
Tealium for Pharma utilizes deep integration technology and partnerships to deliver an enhanced customer journey in one of healthcare's most vital sectors.
Pharmaceutical Technology
JULY 29, 2022
Novartis has expanded its research-based partnership with the University of California, Berkeley, US, to discover new therapeutic modalities and address ‘undruggable’ disease targets. Based on the successes over the last five years, the alliance will develop new technologies to discover next-generation therapies. The merged team of researchers is analysing various disease targets in cancer, as well as other ailments that have escaped conventional small-molecule compounds and drug discovery app
Pharmacy Times
JULY 29, 2022
L-Lysine is a protein source that supports collagen synthesis.
PharmExec
JULY 29, 2022
Founded in 2000, TrialCard is a life sciences commercialization company that provides a comprehensive suite of solutions to over 400 pharma, biotech, and medtech companies.
PharmExec
JULY 29, 2022
Mandy Conver, SVP Business Development for Testing & Analytics, and Jennifer Manning, SVP Global Strategic Partnerships, each bring twenty-plus years of expertise.
Expert insights. Personalized for you.
181 
Let's personalize your content